Ceftaroline

Restricted
C. diff Risk

Medium

Oral Bioavailability

NA

Spectrum Of Activity

Dosing

Requires Infectious Disease consultation for use OR completion of the Restricted Antimicrobial order form for approved indications

600 mg IV every 12 hr

CrCl > 50 ml/minCrCl 31-50 ml/minCrCl 15-30 ml/minCrCl < 15 ml/minNo dose adjustment necessary400 mg IV every 12 hr300 mg IV every 12 hr200 mg IV every 12 hr

200 mg IV every 12 hr

General Information

  • Gram postivie infection resistant to beta-lactams and a serious vancomycin allergy (e.g. anaphylaxis, hives)

  • Failing vancomycin: clinical decompensation or failure after at least 7 days of therapy despite adequate source control and therapeutic levels

  • Failure or intolerance to linezolid or daptomycin

  • Selected over vancomycin in patients with renal failure

  • Hypersenistivty reactions

  • GI effects including diarrhea

Ceftaroline is approved for treatment of skin and skin structure infections (including those caused by MSRA) and community aquired pneumonia.

Lab

  • SCr

Clinical

  • Hypersensitivity

  • Diarrhea

  • GI effects

Pregnancy category: Adverse events have been observed in some animal reproduction studies

Average serum half life: 1.6 hr (single dose), 2.66 hr (multiple doses)

Urine penetration: Excellent

Route of Elimination: Urine